Fort Collins, CO—BGG announced that it has completed and published two clinical trials on its saw palmetto extract

One of the trials was conducted on 44 volunteers who were given either BGG’s saw palmetto or a placebo over an eight-week period (1). The treatment group experienced a statistically significant reduction in urinary issues versus the placebo group.

The second trial established safety at six times the recommended dosage (2).
Related: BAPP Publishes Lab Guidance Doc on Saw Palmetto Extract Healthy and Vibrant — At Every Age Optimizing Urological Health
“We are extremely pleased to offer a saw palmetto extract that has been proven efficacious and safe through peer-reviewed human research," Yanmei Li, Ph.D., BGG’s chief scientific officer, said in a press release. "BGG prides itself not only on producing products with industry-leading quality, but also on sponsoring clinical research to validate our products’ ability to positively affect consumers’ health. This combination of top quality and clinical validation has been extremely well-received by leading brands in the market for our other products, and we look forward to similar success in the saw palmetto category.”


The trials:
  1. Sekikawa, T. Kizawa, Y. Li, Y. Miura, N. (2019). “A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.” Japanese Pharmacology and Therapeutics. 47. 445-452.
  2. Kushima, M. Okamoto, K. Kizawa, Y. Sekikawa, T. Li, Y. Takara, T. (2018) “A Verification Study on the Improvement of Urination Issues with Ingestion of Saw Palmetto Fruit Extract: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study.” Pharmacometrics 95(5/6): 101-111, 2018.